Fig. 1: The GOLP regimen showed high therapeutic efficacy in iCCA. | Nature Communications

Fig. 1: The GOLP regimen showed high therapeutic efficacy in iCCA.

From: Macro CD5L+ deteriorates CD8+T cells exhaustion and impairs combination of Gemcitabine-Oxaliplatin-Lenvatinib-anti-PD1 therapy in intrahepatic cholangiocarcinoma

Fig. 1

A Bar plot showing the overall response rate (ORR) in clinical trials of different first-line therapeutic strategies for iCCA patients. B Workflow of combination therapy of Gemcitabine, Oxaliplatin, Lenvatinib, and anti-PD1 antibody (GOLP) for iCCA patients. Created with BioRender.com. C Representative results of ‘stable disease’ (SD) and ‘partial response’ (PR) iCCA patients at baseline and after 3 cycles of GOLP treatment. SD and PR were evaluated according to the Response Evaluation Criteria in Solid Tumors version 1.1 (RECIST1.1). The arrows indicate the tumors of interest. D Percentage of tumor size reduction after 3 cycles of GOLP treatment in FDU-ZS-ICC-T cohort. Patients evaluated as SD were defined as ‘Poor response’ and the patients evaluated as PR were defined as ‘Well response’. E Workflow of GOLP and other control groups for the treatment of iCCA-bearing mouse with mIC-22 or AY-LTC2. Created with BioRender.com. F Tumor mass after three cycles of different treatments (t test, two-sided). N= 6 biologically independent animals for each group. Source data are provided as a Source Data file.

Back to article page